SU SURAKSHA
Suraksha Diagnostic Q1 2026
SUSURAKSHA

Suraksha Diagnostic Q1 FY26 results (Apr–Jun 2025) and concall

Healthcare · Concall AI · Call held 11 Aug 2025

Management summary

  • Suraksha Diagnostic Limited reported a strong Q1 FY26 with an 18.83% YoY increase in total income to ₹73.49 crores and a 19.67% rise in PAT to ₹9.18 crores.
  • The company expanded its network by 8 new centers, reaching 58, and strategically entered genomic medicine through the acquisition of Fetomat Wellness and the launch of Suraksha Genomics.
  • While new center losses and a shift in B2B/B2C mix impacted revenue per test and diluted overall EBITDA margin to 33.97%, management expects margins to improve as newer centers mature and aims for 15-18 new centers this fiscal year.

Source: Inve concall analysis and management guidance record.

Highlights

  • Total income grew 18.83% YoY to ₹73.49 crores, demonstrating robust top-line growth.

  • EBITDA stood at ₹24.66 crores with a healthy margin of 33.97%.

  • PAT increased 19.67% YoY to ₹9.18 crores, reflecting strong bottom-line performance.

  • Expanded network by adding 8 new centers in Q1 FY26, bringing the total to 58 centers.

Why these two revenue figures differ: Management cited ₹73.5 Cr (Total income) on the call, while the exchange-filed quarterly statement below reports ₹70 Cr — typically due to standalone vs. consolidated scope, revenue from operations vs. total income (including other income), or presentation adjustments.

What they filed

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26
Revenue59 64 70
EBITDA18 20 24
Net profit6 8 10
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Network Expansion

  • New centers to be added Network Expansion · FY26 · High confidence 15-18 centers
  • Total centers Network Expansion · next 2-3 years · Medium confidence 100 centers

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

1 direct
Diagnostic centers vs. hospitals in competitive landscape Direct
The second is the known diagnostic center happens to be at least 30% to 40% cheaper than the hospital diagnostics. So, these are the two main reasons that today the majority of the patients will always approach an independent diagnostic center rather than a hospital.

Explains the competitive advantage of independent diagnostic centers (cost and accessibility) over hospital diagnostics, which is crucial for Suraksha's business model.

Asked by Hitaindra Pradhan

Rental payment for the quarter Partial
So, it varies from, you know, totally other expenses when you see on my financials, which is 17% of my total revenue, which includes around 8% to 9% which is pertaining to rent.

Provides insight into a significant operating cost component (rent) as a percentage of revenue, helping analysts model expenses.

Asked by Hitaindra Pradhan

Unlock risks & concerns, Q2 FY26 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 7 risks, concerns & management red flags
  • 3 watchlist triggers for Q2 FY26
  • +6 more guidance targets & verbatim management quotes
  • +6 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image